Heart and skeletal muscle insulin resistance but not myocardial blood flow reserve could be related to chronic use of thiazolidione in patients with type-2 diabetes*

Ikuo Yokoyama1#, Toshiyuki Moritan2, Yusuke Inoue3

1Department of Cardiovascular Medicine, Clinical Research Center, Sanno Hospital and Sanno Medical Center, International University of Health and Welfare, Tokyo, Japan
2Department of Clinical Engineering, Faculty of Medical Engineering, Suzuka University of Medical Science, Suzuka, Japan
3Department of Radiology, Graduate School of Medicine, Kitasato University, Sagamihara, Japan
Email: #yokochan-tky@umin.ac.jp

Received 3 November 2012; revised 2 December 2012; accepted 14 December 2012

ABSTRACT
Heart and skeletal muscle insulin resistance and abnormal myocardial flow reserve (MFR) occurs in patients with type-II diabetes. Improvement of heart and skeletal muscle insulin resistance with rosiglitazone use over 16 weeks have been reported. However, it is not clear whether chronic use of rosiglitazone can improve heart and skeletal muscle insulin resistance and MFR. Materials and Methods: To test the hypothesis whether effects of rosiglitazone on heart and skeletal muscle insulin resistance and MFR in patients with type-II diabetes, rest and dipyridamole stress perfusion positron emission tomography (PET) with 13N-ammonia and heart and skeletal muscle 18FDG PET scans under insulin clamping were undertaken before and 12 month after the initiation of rosiglitazone therapy (400 mg/day) in 23 patients with type-II diabetes. Twenty patients with type-II diabetes without CAD and without medications were served as controls. In controls, any medications were not added from the first PET study and 12 months after the second PET study. Results: Baseline myocardial blood flow (MBF) was comparable before and after the rosiglitazone group as was the controls. MBF during dipyridamole administration (0.56 mg/min/kg) was not significantly improved in rosiglitazone group and controls. MFR was not improved in rosiglitazone group and controls. In troglitazone group, whole body glucose disposal rate (GDR; µmole/min/kg) significantly improved (pre; 19.0 ± 9.55, post; 28.7 ± 15.3, p < 0.05) as did the skeletal muscle glucose utilization rate (SMGU (µmole/min/kg); pre; 20.3 ± 12.0, post; 34.8 ± 10.6, p < 0.05) and the myocardial glucose utilization rate (MGU (µmole/min/kg); pre; 339.7 ± 105.2 vs. post; 410.0 ± 240.0, p < 0.05). GDR, SMGU and MGU were unchanged in controls. Conclusions: Troglitazone can improve heart and skeletal muscle insulin resistance in patients with type-II diabetes but not MFR showing that co-existence of heart and skeletal muscle insulin resistance is implicated in patients with type-II diabetes and impaired MFR is uncoupled with insulin resistance in the whole body and heart and skeletal muscle in patients with type-II diabetes.

Keywords: Insulin Resistance; Myocardial Insulin Resistance; Glucose; FDG; PET; Type-II Diabetes; Flow Reserve

1. INTRODUCTION
Insulin resistance is defined as an impaired glucose utilization response to the stimulatory effect of insulin and has been recognized to have common essential role in a variety of metabolic diseases including type-II diabetes mellitus [1]. Since insulin resistance is closely related to metabolic syndrome and an occurrence of coronary artery disease (CAD) [2], investigation of the pathophysiology of and effects of certain drugs on insulin resistance is important for an early prevention of CAD.

Positron emission tomography (PET) allows in vivo quantitative analysis of tissue glucose metabolism using [18F]-2-fluoro-2-deoxy-D-glucose (18FDG) and myocardial blood flow (MBF) with 13N-ammonia or 15O-H2O. PET can be used to evaluate insulin resistance and myocardial perfusion abnormalities in subjects highly at risk for CAD. Reduced skeletal muscle glucose utilization (SMGU) under hyperinsulinemic euglycemic clamping,
implying insulin resistance in the skeletal muscle, has been reported in patients with type-II diabetes [3-5]. Reduced myocardial flow reserve (MFR) in patients with type-II diabetes without evidence of CAD [6-8] have also been reported suggesting an existence of microvascular abnormality in the heart.

Effects of rosiglitazone on myocardial insulin resistance in patients with type-II diabetes with CAD have been reported [9]. Effects of pioglitazone on the improvement of whole body insulin resistance and myocardial insulin resistance but not MFR have been reported in patients with familial mixed combined hyperlipidemia [10]. However, another investigation has shown that acute use of troglitazone within 12 weeks failed to improve myocardial insulin resistance although skeletal muscle and whole body insulin resistance were improved in the same study patients with type-II diabetes without CAD [11]. In addition, effects of thiazolidiones on both myocardial insulin resistance and MFR in patients with type-II diabetes with or without CAD are not studied simultaneously. There has been no examination as to whether thiazolidiones can improve heart and skeletal muscle insulin resistance as well as microvascular dysfunction in patients with type-II diabetes during the same study periods. Relatively long term (chronic) effects of thiazolidiones on heart and skeletal muscle insulin resistance and MFR more than 16 weeks have not been done.

This study aimed to study chronic effects of troglitazone therapy over 12 months, on heart and skeletal muscle insulin resistance and MFR in patients with type-II diabetes during the same study periods. Relatively long term (chronic) effects of thiazolidiones on heart and skeletal muscle insulin resistance and MFR in patients with type-II diabetes without CAD have not been done. This study aimed to study chronic effects of troglitazone therapy over 12 months, on heart and skeletal muscle insulin resistance and MFR in patients with type-II diabetes without CAD have not been done.

2. MATERIALS AND METHODS

2.1. Study Design

Study Populations

We recruited asymptomatic non-medicated patients with type-II diabetes from the local clinics and local health service centers. The diabetic patients satisfied the criteria of having a fasting glucose level at admission (within few weeks before the study) greater than 140 mg/dL and hemoglobin A1c (HbA1c) greater than 7.0%. All study subjects were highly negligible for CAD by using treadmill test, rest echocardiography and rest and dipyridamole stress static myocardial perfusion PET.

Twenty-seven patients with type-II diabetes (21 males, 6 females) were recruited for troglitazone therapy group (400 mg/day). Twenty patients with type-II diabetes (16 males, 4 females, HbA1c; 8.0 ± 1.4 percent, age; 52.4 ± 11.2) who had not been and would not be treated with any kinds of medicines for diabetes during the study periods were served as controls from our independent data base to this study. Treadmill test and rest echocardiography were undertaken before the initiation of the study as the initial screening test for CAD and heart diseases. Heart and skeletal muscle 18FDG PET and 13N-ammonia myocardial perfusion PET were undertaken just at the time of initiation of this study and 12 months after the initiation of this study in both groups. Static myocardial perfusion PET images just at the time of the initiation of this study was used to exclude CAD. In both groups, conventional diet and exercise therapy (approximately 10,000 steps/day) were continued during the whole study periods of 12 months between the first PET scan and the second PET scan, therapies were not changed. In case of any kinds of emergency and patient’s request to drop out from this study, the study protocol was stopped. Physical examination and blood check test was undertaken every month during the study periods. Finally, 23 patients with type-II diabetes (mean age 52.9 ± 12.1 yr; 18 males, 5 females, HbA1c; 8.18 ± 1.94 percent, reference value 4.0 - 5.8 percent) finished all of the study protocol using troglitazone therapy and PET scan (3 were excluded due to CAD and 1 was stopped the protocol due to non-fetal side effect of liver damage). General characteristics were shown in Table 1.

Before this study, we informed all subjects of the nature of this study, after which they agreed to participate in the protocol that was approved by the local Ethics Committee.

2.2. Positron Emission Tomography (PET)

Myocardial 13N-ammonia images and heart and skeletal muscle 18FDG images were obtained using a Headtome IV PET scanner (Shimadzu Corp., Kyoto, Japan). This study was used to exclude CAD. In both groups, conventional diet and exercise therapy were not changed. In case of any kinds of emergency and patient’s request to drop out from this study, the study protocol was stopped. Physical examination and blood check test was undertaken every month during the study periods. Finally, 23 patients with type-II diabetes (mean age 52.9 ± 12.1 yr; 18 males, 5 females, HbA1c; 8.18 ± 1.94 percent, reference value 4.0 - 5.8 percent) finished all of the study protocol using troglitazone therapy and PET scan (3 were excluded due to CAD and 1 was stopped the protocol due to non-fetal side effect of liver damage). General characteristics were shown in Table 1.

Before this study, we informed all subjects of the nature of this study, after which they agreed to participate in the protocol that was approved by the local Ethics Committee.

Table 1. General characteristics of study patients with type-II diabetes who were treated with troglitazone therapy.

<table>
<thead>
<tr>
<th></th>
<th>Pre</th>
<th>Post</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (M/F)</td>
<td>23 (18/5)</td>
<td>23 (18/5)</td>
<td>N/A</td>
</tr>
<tr>
<td>Body weight</td>
<td>61.5 ± 8.8</td>
<td>61.8 ± 8.4</td>
<td>NS</td>
</tr>
<tr>
<td>Height</td>
<td>162 ± 7.78</td>
<td>162 ± 7.69</td>
<td>NS</td>
</tr>
<tr>
<td>SBP</td>
<td>134 ± 12.32</td>
<td>129 ± 6.21</td>
<td>NS</td>
</tr>
<tr>
<td>DBP</td>
<td>73.2 ± 10.2</td>
<td>72.5 ± 6.55</td>
<td>NS</td>
</tr>
<tr>
<td>TC</td>
<td>203 ± 19.3</td>
<td>197 ± 20.1</td>
<td>NS</td>
</tr>
<tr>
<td>HDL</td>
<td>53.7 ± 14.7</td>
<td>53.7 ± 13.3</td>
<td>NS</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>161 ± 74.0</td>
<td>153 ± 58.0</td>
<td>NS</td>
</tr>
<tr>
<td>LDL</td>
<td>117 ± 26.1</td>
<td>112 ± 20.9</td>
<td>NS</td>
</tr>
<tr>
<td>HbA1c</td>
<td>8.19 ± 1.18</td>
<td>7.18 ± 0.90</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>FBS</td>
<td>202 ± 47.3</td>
<td>165.2 ± 40.9</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>FFA</td>
<td>0.72 ± 0.29</td>
<td>0.55 ± 0.24</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

N: Number of patients; M: Male; F: Female; N/A: Not applicable; BW: Body weight (kg); HT: Height (cm); BMI: Body mass index (kg/m²); BPS: Systolic blood pressure (mmHg); BPD: Diastolic blood pressure (mmHg); HbA1c: Hemoglobin A1c (percent (%)); FBS: Fasting plasma blood glucose concentration (mg/dL); TC: Total cholesterol (mg/dL); HDL: High density lipoprotein cholesterol; TG: Triglycerides (mg/dL); LDL: Low density lipoprotein cholesterol (mg/dL); NS: Not significant.
PET scanner has seven imaging planes; in-plane resolution is 4.5 mm at full width at half maximum (FWHM) and the z-axial resolution is 9.5 mm at FWHM. Effective in-plane resolution was 7 mm after using a smoothing filter. The sensitivities of the Headtome IV scanners are 14 and 24 kcps (kilo counts/seconds) for direct and cross planes, respectively. After acquiring transmission data for a period of 8 min to correct for photon attenuation prior to obtaining the PET emission images, 15 - 20 mCi of $^{13}$N-ammonia were injected and dynamic PET scanning was performed over 2 min. Fifty-five min after the injection of $^{13}$N-ammonia to allow for decay of the radioactivity of the isotope, dipyridamole (0.56 mg/kg) was administered intravenously over a 4-min period. Five min after the end of the dipyridamole infusion, 15 - 20 mCi of $^{13}$N-ammonia were injected again, and, exactly at the same time, a second dynamic PET scan was performed for 2 min. The dynamic PET scan was performed every 15 sec (8 times) during the 2-min period. Dynamic data were obtained for seven slices. After the dynamic scans, static $^{13}$N-ammonia images were obtained from the PET study over 10 minutes and analyzed visually by three independent specialists who had no other information on the patients. Single channel ECG monitoring in limb leads was performed during the PET study, because a full ECG was not satisfactory due to a lack of a precordial record as a result of a technical difficulty. There was thus the possibility that the ECG data were unreliable and they were therefore not used.

### 2.3. Determination of MBF

Regional MBF was calculated according to the two-compartment $^{13}$N-ammonia tracer kinetic model [12]. The time activity curve of the left ventricular cavity was used as an input function. The tracer spillover was corrected by least square non-linear regression analysis to calculate MBF with the assumption that both myocardial and left ventricular radioactivity influenced one another. Details can be found in our previously published paper [6]. As reported in our previous paper, regions of interest (ROIs) were placed at the septum, anterior wall, lateral wall and infero-posterior wall on transaxial images. To obtain input function, ROIs were placed on the left ventricular cavity of each slice. We determined the MFR value as follows:

\[
\text{MFR} = \frac{\text{MBF during dipyridamole}}{\text{MBF at rest}}
\]

### 2.4. Preparation of $^{18}$FDG

$^{18}$F was synthesized using the Cypris model 370 cyclotron (Sumitomo JYUKI Industries, Ltd., Kyoto, Japan), and $^{18}$FDG was synthesized with an automated system based on the method reported by Ehrenkaufer et al. [13]. Radiochemical purity was more than 95%.

### Acquisition of Myocardial Metabolic Images

There was about 100 min interval after the acquisition of $^{13}$N-ammonia images during dipyridamole administration to allow for decay of radioactivity of $^{13}$N-ammonia during which time the blood glucose concentration was kept constant at the level of about 90 - 105 mg/dl using hyperinsulinemic euglycemic clamp technique which was initiated at the end of data acquisition of MBF during dipyridamole administration. Then a second transmission scan for a period of 10 min was undertaken and we injected $^{18}$FDG (5 - 10 mCi) and collected dynamic PET data for 1 hour and 45 seconds. During this interval, we obtained 19 dynamic scans using the following protocol: five 15-sec, three 30-sec, four 120-sec, four 300-sec and three 600-sec scans.

### 2.5. Quantification of MGU and SMGU to Estimate Heart and Skeletal Muscle Insulin Resistance

The amount of glucose metabolized by various thoracic organs (heart and skeletalmuscle of lumbar region) was determined by calculating the tissue glucose utilization rate. Following the method previously reported by Ohtake et al., [14] we obtained input function from the time activity curve of the descending aorta corrected by seven venous blood samplings. Using the input function, we determined $k_1 \times k_3 / (k_2 + k_3)$ by Patlak graphic analysis [15]. And calculated both the MGU and SMGU by substituting $k_1 \times k_3 / (k_2 + k_3)$ in the following equation.

\[
\text{Tissue}^{18}\text{FDG uptake rate} = \left( k_1 \times k_3 / (k_2 + k_3) \right) \times \left( \text{BG}_1 + \text{BG}_2 + \text{BG}_3 \right) / \text{LC}
\]

$k_1$ and $k_2$ and $k_3$ were rate constants of the following chemical formula.

\[
\text{Glu (S)} \xrightarrow{k_4} \text{Glu-6-phosphate (skelt. M)}
\]

$k_4$ is assumed to be zero in the myocardium and skeletal muscle. $\text{BG}_1$, $\text{BG}_2$ and $\text{BG}_3$ were serum glucose concentrations during the dynamic PET scan using $^{18}$FDG as shown. S means serum and T means tissue. LC stands for Lumped Constant, which was calculated to be 1.0 in myocardium [16] and 1.2 in skeletal muscle cells, as reported in human studies [17].

All PET data were corrected for dead time effects to reduce error to less than 1%. To avoid the influence of the partial volume effect associated with the object's size, recovery coefficients (RC) obtained from experimental phantom studies in our laboratory were used. The RC was 0.8 when myocardial wall thickness was 10 mm. For the correction of the partial volume effect, specialists in
our hospital measured wall thickness with 2-dimensional echocardiography. The RC was taken into consideration in our program to measure the tissue glucose utilization rate.

We obtained the MGU from the transaxial images. The amount of MGU was determined by averaging the above values. We also determined the SMGU from the lumbar muscle according to a previously validated method [18].

To calculate the tissue glucose utilization rate and MBF, we used the SUN Ultra-30 high-speed image processing system (SUN Microsystems Japan Co., Ltd., Tokyo, Japan) with “Dir. View” software (Asahi Kasei Information System Co., Ltd. Tokyo, Japan).

Whole body insulin resistance was determined by obtaining the whole body glucose disposal rate (GDR) during hyperinsulinemic euglycemic clamping (mg/min/kg) using a previously reported method [7]. Twelve months after the initiation of troglitazone therapy, a second PET scan, including 13N-ammonia resting and stress perfusion imaging and heart and skeletal muscle 18FDG PET scan, was undertaken to assess the effect of troglitazone on insulin resistance in the whole body as well as in heart and skeletal muscle and on MFR.

2.6. Power Calculation and Statistical Methods

From our reference data on PET flow measurement, the estimated levels of myocardial blood flow during dipyridamole stress are 250 ± 100 mL/min/100 g in control subjects and 180 ± 51.0 mL/min/100 g in the patients with type-II diabetes mellitus. Assuming that troglitazone therapy will increase myocardial blood flow in the patients with type-II diabetes mellitus to the similar level as in control subjects, to detect statistically significant differences with 80% power and with α = 0.05, a total of 23 patients is required as p = 0.033 with 10% dropout patients. Values are expressed as the mean ± standard deviation. Data before and after therapy were compared by the paired t-test. Differences between two groups were examined by the unpaired t-test or Mann-Whitney test according to the distribution of measurement parameters. Differences between three groups were tested by the multiple comparison method after analysis of variance (ANOVA). A p value of less than 0.05 was considered significant.

3. RESULTS

3.1. GDR, SMGU and MGU

GDR (µmole/min/kg) significantly improved after the troglitazone therapy group (pre; 19.0 ± 9.55, post; 28.7 ± 15.3, p < 0.05) as did the SMGU (pre; 20.3 ± 12.0 µmole/min/kg, post; 34.8 ± 10.6 µmole/min/kg, p < 0.05). MGU also significantly improved after the troglitazone therapy (339.7 ± 105.2 µmole/min/kg (pre) vs. 410.0 ± 240.0 µmole/min/kg (post), p < 0.05).

In control group, GDR (pre; 19.8 ± 9.28, post; 20.5 ± 12.9, p = NS), SMGU (pre; 21.0 ± 12.2 µmole/min/kg, post; 23.4 ± 11.8 µmole/min/kg, p = NS), MGU were not significantly changed 12 months after the first PET scan (341.5 ± 116.3 µmole/min/kg (pre) vs. 358.2 ± 219.5 µmole/min/kg (post), p = NS).

3.2. Baseline MBF and MBF during Dipyridamole Administration and MFR

In the patients with type-II diabetes the baseline MBF (ml/min/100 g) was comparable before and after the troglitazone therapy (pre; 77.6 ± 11.6 vs. post; 74.5 ± 9.62). However, MBF-DP (178 ± 50.9) was not significantly improved (184 ± 61.2, p = NS) after the troglitazone therapy. MFR was not improved by troglitazone (baseline 2.23 ± 0.84 vs. post-therapy 2.27 ± 0.90, p = NS).

In control group, the baseline MBF (ml/min/100 g) was comparable between the first PET scan and the second PET scan (first: 78.5 ± 12.4 vs. the second: 75.9 ± 10.5). MBF-DP in the patients with type-II diabetes (183 ± 54.8) at the time of first PET scan was not significantly changed 12 months after the first PET scan (180 ± 65.1, p = NS). MFR at the time of first PET scan was not changed 12 months after the second PET scan (first 2.29 ± 0.81 vs. the second 2.37 ± 0.94, p = NS).

3.3. Serum Glucose Concentration

Plasma fasting glucose concentration before therapy (8.68 ± 1.87 µmole/liter) was significantly reduced after therapy (7.41 ± 2.21 µmole/liter, p < 0.01). The average serum glucose concentration in patients with type-II diabetes during insulin clamping was (5.08 ± 0.68 µmole/liter). In controls, plasma fasting glucose concentration (8.68 ± 1.87 µmole/liter) at the time of first PET scan was not changed 12 months after the first PET scan (7.41 ± 2.21 µmole/liter, p < 0.01). The average serum glucose concentration in controls during insulin clamping was (5.08 ± 0.68 µmole/liter).

3.4. Serum Insulin Concentration

Serum insulin concentration during insulin clamping was comparable between pre therapy (59.0 ± 17.2 μU/ml) and post therapy (66.3 ± 38.0 μU/ml). There was no significant difference between the serum insulin concentration at the beginning and at the end of the dynamic PET scan. Plasma fasting insulin concentration in patients with type-II diabetes (8.0 ± 3.1 μU/ml) before therapy tended to be decreased compared with pre-therapy values after therapy (7.5 ± 4.1 μU/ml), but remained significantly higher than values for control subjects. There was
no significant relationship between MGU and plasma insulin concentration in the patients with type-II diabetes, as well as between SMGU and plasma insulin concentration.

3.5. Serum Free Fatty Acid Concentration (FFA)

In the patients with type-II diabetes with troglitazone therapy, serum FFA concentration during insulin clamping (0.72 ± 0.29 mEq/liter) was significantly reduced after therapy (0.55 ± 0.24 mEq/liter, p < 0.05).

In control group, serum FFA concentration during insulin clamping was not changed after the therapy (pre; 0.78 ± 0.29 mEq/liter post; 0.75 ± 0.35 mEq/liter, p = NS).

4. DISCUSSION

4.1. General Discussion of Whole Results

This study investigated effects of chronic use of troglitazone on heart and skeletal muscle and whole body insulin resistance and myocardial perfusion in patients with type-II diabetes without CAD during the same study periods for the first time. Data were compared with those who were non-medicated type-II diabetes without CAD. SMGU and GDR were significantly improved 12 months after the troglitazone therapy in patients with type-II diabetes without CAD. These results are consistent with those in vitro findings [19] and our previous study of relatively short-term therapy over 3 months in vivo [20].

On the other hand, in control group, SMGU and GDR were not changed 12 months after the first PET scan. These results showed that chronic troglitazone therapy could also preserve effect to improve the insulin resistance in the skeletal muscle and whole body in patients with type-II diabetes without CAD. In addition, MGU was also improved significantly in the troglitazone therapy group but such improvement was not seen in control group. These results highly suggest that chronic use of troglitazone can improve insulin resistance in both the heart and skeletal muscle and whole body in patients with type-II diabetes without CAD. Similar investigation has been done in patients with type-II diabetes with CAD using rosiglitazone [9]. In the report, effects of rosiglitazone on the heart and skeletal muscle insulin resistance have been investigated over 16 weeks (relatively short term periods of therapy comparing with our present study) in patients with type-II diabetes with CAD [9].

Naoumova et al. reported that pioglitazone improved heart and whole body insulin resistance but not MFR in patients with familial combined hyperlipidemia but not type-II diabetes [10]. Whereas Yokoyama et al. reported that troglitazone therapy within 12 weeks improved skeletal muscle and whole body insulin resistance but not myocardial insulin resistance [11]. Therefore, it takes long time to improve myocardial insulin resistance with troglitazone in type-II diabetes.

4.2. Influence of a Co-Existence of CAD on Myocardial Insulin Resistance in Type-II Diabetes

No significant difference in MGU has been observed between normal remote myocardial segments in patients with CAD and type-II diabetes and normal remote myocardial segments in patients with CAD without type-II diabetes [21]. So it should be needed to negate the influence of a co-existence of CAD on the thiazolidione’s response to myocardial insulin resistance. Whereas, it has not been clear whether myocardial insulin resistance could be altered by the co-existence of CAD in patients with type-II diabetes. Therefore, effects of thiazolidiones on heart and skeletal muscle insulin resistance in patients with type-II diabetes without CAD has been remain uncertain. In addition, effects of any kinds of thiazolidiones over relatively long-term therapy periods (12 months) on heart and skeletal muscle and whole body insulin resistance in patients with type-II diabetes without CAD have not been studied. As results of this study, relatively long term therapy of troglitazone can improve both whole body insulin resistance and myocardial insulin resistance significantly in patients with type-II diabetes without CAD. Since troglitazone is one of thiazolidiones which act as an insulin sensitomer, our results strongly support that both heart and skeletal muscle and whole body insulin resistance coexists in patients with type-II diabetes without CAD. Furthermore, our results support such reports that showed an existence of myocardial insulin resistance in patients with type-II diabetes who also had skeletal muscle and whole body insulin resistance [3-5].

The plasma FFA concentration was reported to be related to insulin resistance in patients with type-II diabetes [22,23]. Enhancement of insulin stimulated suppressive effect to decrease FFA via PPAR-gamma agonists has been reported [24]. In our current study, the plasma FFA concentration during insulin clamping was significantly decreased 12 months after the troglitazone therapy and both heart and skeletal muscle glucose utilization and GDR were significantly increased in the troglitazone therapy group however no changes were seen in the control group. These results indicate that the FFA concentration is a factor in the improvement of insulin resistance in both the whole body and the heart and skeletal muscle after the administration of troglitazone. An existence of glucose-FFA cycle (so-called Randle’s cycle) has been reported in human heart and skeletal muscle [25]. Our current results suggest that troglitazone improves insulin resistance in the heart and skeletal muscle and the whole body.
body inpatients with type-II diabetes without CAD via an enhancement of the Randle’s cycle.

Another possible mechanisms to increase SMGU, MGU and GDR by troglitazone use over 12 months could be thought as follows. An activation of the peroxisome proliferator-activated receptor (PPAR-γ) in adipocytes [26], an increase in the number of small adipocytes and inactivation of tumor necrotizing factor-α (TNF-α) via the activation of PPAR-γ in adipocytes [26] can be factors. Up-regulation of gene expression of PPAR-γ in skeletal muscle cells by troglitazone may be another mechanism for the improvement of SMGU in patients with type-II diabetes. However, since adipocytes scarcely exist in the heart, this discussion would not be applied to mechanisms of improvement in MGU with troglitazone. Further investigation should be required to improve heart and skeletal muscle insulin resistance in patients with type-II diabetes without CAD after troglitazone therapy.

4.3. Troglitazone Did Not Improve MFR in Patients with Type-II Diabetes without CAD

In this study, MFR was not improved in troglitazone therapy group, contrasting to the results of an improvement of insulin resistance in the whole body and heart and skeletal muscle. In addition, MFR, MGU, SMGU and GDR were not improved in the control group. Those findings led to the expectation that the recovery of MFR would not be related to the improvement of insulin resistance not only in the whole body but also in heart and skeletal muscle after troglitazone in patients with type-II diabetes. On the other hand, glycemic control has been implicated to be related to the reduced MFR in patients with type II diabetes [6-8], but not to the whole body insulin resistance [7,8]. Therefore, our current results that troglitazone did not improve MFR in patients with type-II diabetes but improved only insulin resistance in the whole body highly support above studies. Moreover, our present results have shown that the improvement of heart or skeletal muscle insulin resistance does not lead to recovery of MFR in patients with type-II diabetes. In general, a reduced MFR is thought to be principally due to a structural alteration in the microvascular bed surface area due to micro embolism and/or atherosclerosis or both. Contrary to anti-hyperlipidemic therapies which have been reported to improve MFR in patients with hyperlipidemia without CAD [27-29] and those with CAD, [30,31] anti-diabetic therapies do not cure hyperglycemia and/or insulin resistance completely and the deleterious effects of diabetes on vessels might progress gradually day by day. These factors can be a reason in our result as to the no effect of troglitazone therapy on the recovery of MFR in type-II diabetes. In patients with CAD and hyper-LDL cholesterolemia, delayed response of improvement of MFR in response to lipid-lowering therapy with fluvastatin has been reported [31]. It has also been reported that reduced MFR in patients with hypercholesterolemia and CAD was improved by simvastatin but not by pravastatin [29]. Therefore, kinds of drugs and duration of therapy can also be factors for the improvement of MFR. Our current results support the knowledge that abnormal coronary microvascular function is mainly related to glycemic control in patients with type-II diabetes but not to insulin resistance [7,8]. These results suggested that much stronger and stable effects on hyperglycemia and much longer therapeutic periods should be required to improve MFR in patients with type-II diabetes rather than modest improvements in glycemic control and insulin resistance. It has been reported that abnormal microvascular function in patients with type-II diabetes should be un-resolved important question to answer [32]. Much stronger evidence should be required how to treat abnormal microvascular dysfunction in patients with type-II diabetes.

4.4. Quantitative Analysis of Heart and Skeletal Muscle Glucose Utilization Using PET and 18FDG

The significant improvement of both SMGU and GDR indicates the validity of the PET quantitative method to measure SMGU. However, previous animal experimental studies suggested that the myocardial Lumped Constant, which strands for the difference between glucose and 18FDG, is not constant [33,34]. Hariharan et al. only showed that the bolus injection of insulin (but not insulin clamping) did not increase myocardial 18FDG uptake, whereas myocardial glucose uptake was increased spontaneously when a resected beating mouse heart was perfused by Krebs Henseelite buffer [33]. However, clinical myocardial 18FDG PET studies have shown that insulin clamping effectively increased myocardial 18FDG uptake in both normal controls and patients with type II diabetes [3-5]. The method used in the animal studies [33,34] cannot be applied to human studies. Furthermore, Ng et al. have revealed that 18FDG uptake quite linearly correlated with myocardial glucose uptake [34]. Therefore, the animal experimental findings can only suggest that MGU cannot be measured by PET and 18FDG after bolus injection of insulin but they did not determine if MGU can be measured by PET and 18FDG under hyperinsulinemic euglycemic clamping.

In this study, we determined SMGU from the lumbar muscle, because with this approach both MGU and SMGU can be measured just at the same time with nearly the same accuracy as that of thigh muscle [18]. In the manuscript of this method, a significant positive relationship between thigh muscle SMGU and lumbar mus-
smallest SMGU and no significant difference in SMGU value between thigh muscle and lumbar muscle have been shown [18]. Therefore, determination of SMGU from the lumbar muscle can be considered to be reliable. Orientation of lumbar muscle can be determined with static 18F images after the dynamic study by changing the color scale appropriately, so there is no problem as to the placement of ROI. Even when orientation of lumbar muscle is difficult to determine only by PET, X-ray CT is very helpful to the ROI placement. Several reports cite measurement of SMGU from the femoral muscle. [4,5,11,25,35] However, this approach requires additional data acquisition time over 22 - 30 min after the PET scan of thoracic region, including frequent arterial or arterialized or venous blood samplings to obtain input function and dynamic data of femoral muscle 18F uptake.

4.5. Study Limitation

Since this study is open trial and not a placebo-control double blind study, grade of evidences obtained from this study would be under estimated. Because of serious liver damage of troglitazone, we did not make such strict trial and disappeared from the market. These are the limitation of this study.

5. CONCLUSION

Chronic troglitazone use can improve heart and skeletal muscle insulin resistance similarly but not MFR in patients with type-II diabetes. These results lead an idea that myocardial insulin resistance co-exists with skeletal muscle and whole body insulin resistance in patients with type-II diabetes without CAD. No change of MFR after troglitazone therapy indicated that MFR was uncoupled with the recovery of insulin resistance in the whole body and heart and skeletal muscle in patients with type-II diabetes without CAD.

REFERENCES


[8] Yokoyama, I., Yonekura, K., Ohtake, T., et al. (2000) Myocardial flow reserve in angiographically normal coronary arteries in non-insulin-dependent diabetics was related to glycemic control and was more prominently reduced in those with microvascular angina than in those with coronary artery disease. Journal of Nuclear Cardiology, 41, 978-985.


[27] Yokoyama, I., Momomura, S., Ohtake, T., et al. (1999) Improvement of myocardial vasodilatation in hyperlipidemias due to diffuse coronary arterosclerosis after lipid lowering therapy. *Circulation*, 100, 117-122. doi:10.1161/01.CIR.100.2.117


Copyright © 2013 SciRes. OPEN ACCESS